Wells Fargo’s Denali Therapeutics DNLI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $4.88M | Buy |
189,865
+82,208
| +76% | +$1.69M | ﹤0.01% | 2869 |
|
|
2026
Q1 | $2.07M | Sell |
107,657
-86,024
| -44% | -$1.71M | ﹤0.01% | 3237 |
|
|
2025
Q4 | $3.2M | Buy |
193,681
+89,502
| +86% | +$1.51M | ﹤0.01% | 3066 |
|
|
2025
Q3 | $1.51M | Buy |
104,179
+14,540
| +16% | +$209K | ﹤0.01% | 3517 |
|
|
2025
Q2 | $1.25M | Buy |
89,639
+12,357
| +16% | +$174K | ﹤0.01% | 3548 |
|
|
2025
Q1 | $1.05M | Sell |
77,282
-11,651
| -13% | -$223K | ﹤0.01% | 3622 |
|
|
2024
Q4 | $1.81M | Sell |
88,933
-4,764
| -5% | -$122K | ﹤0.01% | 3268 |
|
|
2024
Q3 | $2.73M | Buy |
93,697
+19,376
| +26% | +$480K | ﹤0.01% | 2822 |
|
|
2024
Q2 | $1.73M | Buy |
74,321
+9,538
| +15% | +$183K | ﹤0.01% | 3098 |
|
|
2024
Q1 | $1.33M | Sell |
64,783
-1,582
| -2% | -$29.7K | ﹤0.01% | 3265 |
|
|
2023
Q4 | $1.42M | Sell |
66,365
-69,561
| -51% | -$1.38M | ﹤0.01% | 3178 |
|
|
2023
Q3 | $2.8M | Sell |
135,926
-26,628
| -16% | -$675K | ﹤0.01% | 2536 |
|
|
2023
Q2 | $4.8M | Buy |
162,554
+37,484
| +30% | +$1.05M | ﹤0.01% | 2180 |
|
|
2023
Q1 | $2.88M | Buy |
125,070
+60,381
| +93% | +$1.66M | ﹤0.01% | 2563 |
|
|
2022
Q4 | $1.8M | Sell |
64,689
-198
| -0.3% | -$5.89K | ﹤0.01% | 2853 |
|
|
2022
Q3 | $1.99M | Sell |
64,887
-4,319
| -6% | -$140K | ﹤0.01% | 2742 |
|
|
2022
Q2 | $2.04M | Sell |
69,206
-41,062
| -37% | -$1.08M | ﹤0.01% | 2774 |
|
|
2022
Q1 | $3.55M | Sell |
110,268
-33,268
| -23% | -$1.14M | ﹤0.01% | 2759 |
|
|
2021
Q4 | $6.4M | Sell |
143,536
-21,209
| -13% | -$1M | ﹤0.01% | 2317 |
|
|
2021
Q3 | $8.31M | Buy |
164,745
+16,972
| +11% | +$957K | ﹤0.01% | 2379 |
|
|
2021
Q2 | $11.6M | Buy |
147,773
+31,649
| +27% | +$1.96M | ﹤0.01% | 2114 |
|
|
2021
Q1 | $6.63M | Sell |
116,124
-7,570
| -6% | -$507K | ﹤0.01% | 2564 |
|
|
2020
Q4 | $10.4M | Buy |
123,694
+37,945
| +44% | +$2.29M | ﹤0.01% | 2057 |
|
|
2020
Q3 | $3.07M | Buy |
85,749
+5,750
| +7% | +$173K | ﹤0.01% | 2967 |
|
|
2020
Q2 | $1.94M | Sell |
79,999
-79,340
| -50% | -$1.87M | ﹤0.01% | 3281 |
|
|
2020
Q1 | $2.79M | Buy |
159,339
+14,082
| +10% | +$294K | ﹤0.01% | 2729 |
|
|
2019
Q4 | $2.53M | Sell |
145,257
-631
| -0.4% | -$10.5K | ﹤0.01% | 3156 |
|
|
2019
Q3 | $2.23M | Buy |
145,888
+6,464
| +5% | +$123K | ﹤0.01% | 3234 |
|
|
2019
Q2 | $2.9M | Buy |
139,424
+66,773
| +92% | +$1.5M | ﹤0.01% | 3025 |
|
|
2019
Q1 | $1.69M | Sell |
72,651
-1,859
| -2% | -$38.9K | ﹤0.01% | 3494 |
|
|
2018
Q4 | $1.54M | Buy |
74,510
+5,180
| +7% | +$94K | ﹤0.01% | 3496 |
|
|
2018
Q3 | $1.51M | Buy |
69,330
+13,410
| +24% | +$222K | ﹤0.01% | 3649 |
|
|
2018
Q2 | $853K | Buy |
55,920
+273
| +0.5% | +$5.14K | ﹤0.01% | 4106 |
|
|
2018
Q1 | $1.1M | Buy |
55,647
+15,947
| +40% | +$328K | ﹤0.01% | 3841 |
|
|
2017
Q4 | $621K | Buy |
+39,700
| New | +$713K | ﹤0.01% | 4239 |
|
Other funds holding DNLI
Wells Fargo's DNLI Position: Q2 2026 in Review
Wells Fargo increased its Denali Therapeutics (DNLI) stake by 76% in Q2 2026, buying an estimated $1.69M and bringing the position to 189,865 shares worth $4.88M. The position accounts for ﹤0.01% of the portfolio, ranked #2869.
Wells Fargo first reported a position in DNLI in Q4 2017 and has held it in 35 quarters since. The position peaked at $11.6M in Q2 2021. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.
- Wells Fargo held 189,865 shares of Denali Therapeutics worth $4.88M as of Q2 2026.
- Wells Fargo bought 82,208 Denali Therapeutics shares in Q2 2026, an estimated $1.69M.
- Denali Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #2869 holding.
- Wells Fargo first reported a position in Denali Therapeutics in Q4 2017 and has held it in 35 quarters since.
- Wells Fargo's Denali Therapeutics position peaked at $11.6M in Q2 2021.
- 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.
Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.